Congress should reject legislation that nominally would let the government negotiate Medicare drug prices because the real effect would be price controls, Heritage Foundation senior fellow Robert E. Moffit writes. Part D has reduced costs with its competitive structure, surpassed expectations in terms of health plan participation and lowered premiums.

Related Summaries